53 related articles for article (PubMed ID: 7645263)
21. Association of Epstein-Barr virus early antigen diffuse component and virus-specified DNA polymerase activity.
Li JS; Zhou BS; Dutschman GE; Grill SP; Tan RS; Cheng YC
J Virol; 1987 Sep; 61(9):2947-9. PubMed ID: 3039183
[TBL] [Abstract][Full Text] [Related]
22. [Cell fusion and activation of Epstein-Barr virus (EBV)].
Liu YX
Zhonghua Zhong Liu Za Zhi; 1985 Jan; 7(1):15-8. PubMed ID: 2983958
[No Abstract] [Full Text] [Related]
23. Characterization of two monoclonal antibodies to Epstein-Barr virus diffuse early antigen which react to two different epitopes and have different biological function.
Tsai CH; Williams MV; Glaser R
J Virol Methods; 1991 Jun; 33(1-2):47-52. PubMed ID: 1719014
[TBL] [Abstract][Full Text] [Related]
24. Phosphorylation of the Epstein-Barr virus (EBV) DNA polymerase processivity factor EA-D by the EBV-encoded protein kinase and effects of the L-riboside benzimidazole 1263W94.
Gershburg E; Pagano JS
J Virol; 2002 Feb; 76(3):998-1003. PubMed ID: 11773375
[TBL] [Abstract][Full Text] [Related]
25. Expression of an early Epstein-Barr virus antigen (EA-D) in E. coli. Brief report.
Roeckel D; Boos H; Mueller-Lantzsch N
Arch Virol; 1987; 97(3-4):365-72. PubMed ID: 2827613
[TBL] [Abstract][Full Text] [Related]
26. Neutralization of Epstein-Barr virus-induced ribonucleotide reductase with antibody to the major restricted early antigen polypeptide.
Goldschmidts WL; Ginsburg M; Pearson GR
Virology; 1989 May; 170(1):330-3. PubMed ID: 2541553
[TBL] [Abstract][Full Text] [Related]
27. Biochemical characterization of two Epstein-Barr virus early antigen-associated phosphopolypeptides.
Roeckel D; Mueller-Lantzsch N
Virology; 1985 Dec; 147(2):253-63. PubMed ID: 2416113
[TBL] [Abstract][Full Text] [Related]
28. Fusion of EBV with the surface of receptor-negative human hepatoma cell line Li7A permits virus penetration and infection.
Lisi A; Pozzi D; Carloni G; Da Villa G; Iacovacci S; Valli MB; Grimaldi S
Res Virol; 1995; 146(4):295-300. PubMed ID: 8539493
[TBL] [Abstract][Full Text] [Related]
29. Quantitative analysis of the Epstein-Barr virus-inducing properties of short-chain fatty acids present in the culture fluids of oral bacteria.
Asai S; Nakamura Y; Yamamura M; Ikezawa H; Namikawa I
Arch Virol; 1991; 119(3-4):291-6. PubMed ID: 1652240
[TBL] [Abstract][Full Text] [Related]
30. Comparative Analysis of the Humoral Immune Response to the EBV Proteome across EBV-Related Malignancies.
Argirion I; Pfeiffer RM; Proietti C; Coghill AE; Yu KJ; Middeldorp JM; Sarathkumara YD; Hsu WL; Chien YC; Lou PJ; Wang CP; Rothman N; Lan Q; Chen CJ; Mbulaiteye SM; Jarrett RF; Glimelius I; Smedby KE; Hjalgrim H; Hildesheim A; Doolan DL; Liu Z
Cancer Epidemiol Biomarkers Prev; 2023 May; 32(5):687-696. PubMed ID: 36788424
[TBL] [Abstract][Full Text] [Related]
31. The SWI/SNF Chromatin Regulator BRG1 Modulates the Transcriptional Regulatory Activity of the Epstein-Barr Virus DNA Polymerase Processivity Factor BMRF1.
Su MT; Wang YT; Chen YJ; Lin SF; Tsai CH; Chen MR
J Virol; 2017 May; 91(9):. PubMed ID: 28228591
[TBL] [Abstract][Full Text] [Related]
32. Tetrameric ring formation of Epstein-Barr virus polymerase processivity factor is crucial for viral replication.
Nakayama S; Murata T; Yasui Y; Murayama K; Isomura H; Kanda T; Tsurumi T
J Virol; 2010 Dec; 84(24):12589-98. PubMed ID: 20926567
[TBL] [Abstract][Full Text] [Related]
33. Epstein-Barr virus polymerase processivity factor enhances BALF2 promoter transcription as a coactivator for the BZLF1 immediate-early protein.
Nakayama S; Murata T; Murayama K; Yasui Y; Sato Y; Kudoh A; Iwahori S; Isomura H; Kanda T; Tsurumi T
J Biol Chem; 2009 Aug; 284(32):21557-68. PubMed ID: 19491105
[TBL] [Abstract][Full Text] [Related]
34. The Epstein-Barr virus protein BMRF1 activates gastrin transcription.
Holley-Guthrie EA; Seaman WT; Bhende P; Merchant JL; Kenney SC
J Virol; 2005 Jan; 79(2):745-55. PubMed ID: 15613302
[TBL] [Abstract][Full Text] [Related]
35. Characterization of human herpesvirus 8 ORF59 protein (PF-8) and mapping of the processivity and viral DNA polymerase-interacting domains.
Chan SR; Chandran B
J Virol; 2000 Dec; 74(23):10920-9. PubMed ID: 11069986
[TBL] [Abstract][Full Text] [Related]
36. Activation of the BRLF1 promoter and lytic cycle of Epstein-Barr virus by histone acetylation.
Chang LK; Liu ST
Nucleic Acids Res; 2000 Oct; 28(20):3918-25. PubMed ID: 11024171
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.
Zacny VL; Gershburg E; Davis MG; Biron KK; Pagano JS
J Virol; 1999 Sep; 73(9):7271-7. PubMed ID: 10438815
[TBL] [Abstract][Full Text] [Related]
38. Regulation of Epstein-Barr virus promoters in oral epithelial cells and lymphocytes.
Lagenaur LA; Palefsky JM
J Virol; 1999 Aug; 73(8):6566-72. PubMed ID: 10400753
[TBL] [Abstract][Full Text] [Related]
39. Alteration of a single serine in the basic domain of the Epstein-Barr virus ZEBRA protein separates its functions of transcriptional activation and disruption of latency.
Francis AL; Gradoville L; Miller G
J Virol; 1997 Apr; 71(4):3054-61. PubMed ID: 9060666
[TBL] [Abstract][Full Text] [Related]
40. Functional and physical interactions between the Epstein-Barr virus (EBV) proteins BZLF1 and BMRF1: Effects on EBV transcription and lytic replication.
Zhang Q; Hong Y; Dorsky D; Holley-Guthrie E; Zalani S; Elshiekh NA; Kiehl A; Le T; Kenney S
J Virol; 1996 Aug; 70(8):5131-42. PubMed ID: 8764021
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
